---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-033868"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2026-05-12T11:07:44+00:00"
generated_at: "2026-05-12T11:11:49.705917+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acumen posts Q1 net loss $20.7M; Phase 2 AD topline results expected late 2026

## Summary
- Cash and marketable securities totaled $128.4M as of Mar 31, 2026; funded into early 2027.
- Net loss $20.7M for Q1 2026 vs $28.8M in Q1 2025; R&D expense fell to $16.5M from $25.3M.
- Topline results from Phase 2 ALTITUDE-AD study (sabirnetug, early Alzheimer's) due late 2026.
- Option to license two candidates from JCR EBD collaboration expected in Q2 2026.
- Targeting IND filing for EBD lead candidate in mid-2027.

## SEC filing metadata
- accession: 0001628280-26-033868
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2026-05-12T11:07:44+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/0001628280-26-033868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/abos-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-033868
- JSON: https://secwatch.observer/filing/0001628280-26-033868.json
- Plain text: https://secwatch.observer/filing/0001628280-26-033868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.